

Amendments to the Claims

1. (currently amended) A method for the treatment of a disorder of the eye comprising:
administering to a subject a therapeutically effective amount of a composition comprising a dsRNA between 21 and 23 nucleotides in length and a carrier, said dsRNA having a nucleotide sequence corresponding to mRNA of SEQ ID NO: 3 ~~a target gene expressed in the eye~~; said administering of the composition occurring outside the blood-retina barrier, and said composition inhibiting ~~the target gene~~ by RNA interference inside the eye.
- 2.-3. (canceled)
4. (previously presented) The method of claim 1, wherein said disorder is related to angiogenesis and/or neovascularization.
5. (previously presented) The method of claim 1, wherein said disorder is related to the retinal pigment epithelium (RPE), neurosensory retina, choroid, and a combination thereof.
6. (previously presented) The method of claim 1, wherein said disorder is wet age-related macular degeneration (AMD) or diabetic retinopathy.
- 7.-8. (canceled)
9. (currently amended) The method of claim 1, wherein said dsRNA is an inhibitor of expression of SEQ ID NO: 3 ~~the target gene~~.
10. (currently amended) The method of claim 9, wherein said inhibitor inhibits expression of the ~~target gene~~ SEQ ID NO: 3 involved in angiogenesis and/or neovascularization.
- 11.-15. (canceled)
16. (previously presented) The method of claim 1, wherein the dsRNA comprises a terminal 3'-hydroxyl group.
- 17.-93. (canceled)
94. (withdrawn) The method of claim 1, further comprising preparing the dsRNA.

95. (withdrawn) The method of claim 1, further comprising diagnosing a subject with a disorder or a predisposition to a disorder of the eye.
96. (currently amended) The method of claim 1, further comprising detecting a product of SEQ ID NO: 3 ~~the target gene~~.
97. (withdrawn) The method of claim 1, further comprising isolating the target gene.
98. (previously presented) The method of claim 1, wherein said administering is by systemic administration.